Drugs / Semaglutide B
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT05478252 Comparator | Aug 2022 → Aug 2023 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Semaglutide B | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05478252 ↗ |
| Route | Subcutaneous | “subcutaneous injections” NCT05478252 ↗ |